Sökning: onr:"swepub:oai:DiVA.org:oru-88081" >
Smart Insulin Pens ...
Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden : A Cost-Effectiveness Analysis
-
- Jendle, Johan, 1963- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper
-
- Ericsson, Åsa (författare)
- Novo Nordisk Scandinavia AB, Malmö, Sweden
-
- Gundgaard, Jens (författare)
- Novo Nordisk A/S, Søborg, Denmark
-
visa fler...
-
- Møller, Jonas Bech (författare)
- Novo Nordisk A/S, Søborg, Denmark
-
- Valentine, William J. (författare)
- Ossian Health Economics and Communications, Basel, Switzerland
-
- Hunt, Barnaby (författare)
- Ossian Health Economics and Communications, Basel, Switzerland
-
visa färre...
-
(creator_code:org_t)
- 2020-12-11
- 2021
- Engelska.
-
Ingår i: Diabetes Therapy. - : Springer. - 1869-6953 .- 1869-6961. ; 12:1, s. 373-388
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://link.springe...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- INTRODUCTION: Real-world evidence has demonstrated improved glycemic control and insulin management following introduction of smart insulin pens in a Swedish type 1 diabetes (T1D) population. To understand the implications for healthcare costs and expected health outcomes, this analysis evaluated the long-term cost-effectiveness of introducing smart insulin pens to standard-of-care T1D treatment (standard care) from a Swedish societal perspective.METHODS: Clinical outcomes and healthcare costs (in 2018 Swedish krona, SEK) were projected over patients' lifetimes using the IQVIA CORE Diabetes Model to estimate cost-effectiveness. Clinical data and baseline characteristics for the simulated cohort were informed by population data and a prospective, noninterventional study of a smart insulin pen in a Swedish T1D population. This analysis captured direct and indirect costs, mortality, and the impact of diabetes-related complications on quality of life.RESULTS: Over patients' lifetimes, smart insulin pen use was associated with per-patient improvements in mean discounted life expectancy (+ 0.90 years) and quality-adjusted life expectancy (+ 1.15 quality-adjusted life-years), in addition to mean cost savings (direct, SEK 124,270; indirect, SEK 373,725), versus standard care. A lower frequency and delayed onset of complications drove projected improvements in quality-adjusted life expectancy and lower costs with smart insulin pens versus standard care. Overall, smart insulin pens were a dominant treatment option relative to standard care across all base-case and sensitivity analyses.CONCLUSIONS: Use of smart insulin pens was projected to improve clinical outcomes at lower costs relative to standard care in a Swedish T1D population and represents a good use of healthcare resources in Sweden.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- Diabetes complications
- Diabetes self-management
- Diabetes technology
- Digital health
- Health technology assessment
- Healthcare economics
- Hypoglycemia
- Insulin therapy
- Type 1 diabetes
- eHealth
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas